Clinical trials
Myelodysplastic Syndromes clinical trials
Below are recruiting myelodysplastic syndromes clinical trials, each written for real people, not researchers. We’re tracking 283 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07044544RecruitingPhase 1
New drug combo in stem cell transplant for myeloid cancers
This trial tests adding two new drugs, decitabine and venetoclax, to a standard reduced-intensity stem cell transplant for people with certain types of leukemia or myelodysplastic syndrome. The goal is to see if this combination can improve outcomes.
Birmingham, AlabamaAges 18–75 - NCT07046078RecruitingPhase 2
Chemo, radiation, and donor transplant for older adults with high-risk AML
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
Seattle, WashingtonAges 18 years+ - NCT07096297RecruitingPhase 2
Testing two drugs for lower-risk MDS
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
New Haven, ConnecticutAges 18 years+ - NCT07121140Recruiting
Home blood transfusions for cancer patients
This trial tests whether it is safe to give blood transfusions at home instead of in the hospital. It is for people who need regular blood transfusions for their cancer care.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07155226RecruitingPhase 1/Phase 2
Study of AZD3632 for advanced blood cancers with certain gene changes
This trial is testing a new drug, AZD3632, either alone or with other cancer treatments, for people with advanced blood cancers that have specific genetic changes (like KMT2Ar, NPM1m, or others that cause HOX over-expression). The goal is to see if it can help when standard treatments have stopped working.
Decatur, IllinoisAges 16 years+ - NCT07205523Recruiting
High-altitude blood study for stem cell transplant patients
This study observes how blood and stem cell transplants work for patients with blood diseases at high altitude. It aims to learn more to help future patients.
Xining, QinghaiAges Any age - NCT07228273RecruitingPhase 2
A new drug combo for AML and high-risk MDS
This trial combines three standard chemotherapy drugs (fludarabine, cytarabine, idarubicin) with a targeted therapy (venetoclax) to treat acute myeloid leukemia (AML) and a related condition called MDS with high blast counts. The goal is to see if adding venetoclax improves results.
Portland, OregonAges 18–65 - NCT07238712RecruitingPhase 2
New drug combo for high-risk blood cancer transplant
This trial tests a new combination of two chemotherapy drugs (bendamustine and cyclophosphamide) given before a stem cell transplant to help prevent graft-versus-host disease. It is for people with high-risk blood cancers who don't have a fully matched donor and will receive a partially matched transplant.
Saint PetersburgAges 18–70 - NCT07238686RecruitingPhase 2
Venetoclax plus microtransplant for higher-risk MDS
This study tests a combination of venetoclax (a targeted drug) with a mini stem cell transplant (called a microtransplant) using a partially matched donor. It is for people with higher-risk MDS who cannot have a standard transplant.
BeijingAges 18 years+ - NCT07270978RecruitingPhase 1
CD33-targeting cells for leukemia with leftover cancer cells
This trial tests a new treatment using special immune cells that target a protein called CD33 on leukemia cells. It's for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who still have small amounts of cancer cells left after other treatments.
Charlottesville, VirginiaAges 18 years+ - NCT07283094RecruitingPhase 1
FHD-286 with decitabine and venetoclax for AML
This early-phase trial tests a new study drug called FHD-286 combined with two standard AML medicines (decitabine and venetoclax). It is for people with a high-risk type of AML that is either newly diagnosed (and you cannot have strong chemotherapy) or has come back after one prior treatment.
The Bronx, New YorkAges 18 years+ - NCT07285044RecruitingPhase 2
Home cancer treatment program for Florida panhandle residents
This study tests whether people with certain cancers can safely receive their regular intravenous treatments at home instead of coming to the clinic. It aims to make treatment more convenient and improve satisfaction, especially for those living in the Florida Panhandle.
Jacksonville, FloridaAges 18 years+ - NCT07297576Recruiting
Sulforaphane to speed blood recovery after cord blood transplant
This trial tests if a natural compound called sulforaphane can help your blood cells recover faster after a cord blood transplant for high-risk blood cancers. If you qualify, you would receive this supplement along with your transplant.
TianjingAges 18 years+ - NCT07301866RecruitingPhase 1/Phase 2
Testing an improved dose of UM171 for cord blood transplant
This trial tests a higher dose of UM171 to make cord blood transplants safer and more effective for people with certain blood cancers or bone marrow diseases. It aims to help patients who don't have a suitable donor.
Montreal, QuebecAges 18–67 - NCT07321626RecruitingPhase 1
Romiplostim for platelet recovery after stem cell transplant
This trial tests if romiplostim, a drug that helps the body make platelets, can speed up platelet recovery after a special type of stem cell transplant from a half-matched donor. It may help reduce bleeding risk during the recovery period.
HangzhouAges 18 years+ - NCT03802695RecruitingPhase 1
Orca-Q pill to help during stem cell transplant
This Phase 1 trial studies Orca-Q to see if it is safe and works when added around the time of an allogeneic (donor) stem cell transplant for certain blood cancers. If you qualify, the study may offer a new option for managing the transplant immune response.
Duarte, CaliforniaAges 12–78 - NCT06996119RecruitingPhase 1
Preventing graft-versus-host disease after stem cell transplant
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
Duarte, CaliforniaAges 18–75 - NCT07347171RecruitingPhase 1
Testing CG009301 for blood cancers that returned or didn't respond
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
NanchangAges 18–75 - NCT01890486Recruiting
Collecting information from people having a stem cell transplant
This study aims to collect, store, and share data from patients who are receiving standard intensive treatment and a stem cell transplant from either their own cells or a donor. It may help improve how future patients are treated by building a reliable record of outcomes and care patterns.
Winston-Salem, North CarolinaAges 18–120 - NCT01137825Recruiting
Older patient cancer registry for a health check
This study is a registry that collects information from older adults who may be dealing with cancer. It includes a short health and function check to help doctors understand needs and guide care, even for people who turn out not to have cancer.
Boone, North CarolinaAges 65 years+ - NCT01210274Recruiting
Study how people resist azacitidine in blood cancers
This study looks at why some people with higher-risk blood cancers (MDS/AML-MD) do not respond as well to azacitidine. The goal is to learn the causes of resistance so future treatments may work better.
AntibesAges 18 years+ - NCT01515527RecruitingPhase 2
Cladribine plus low-dose cytarabine and decitabine for AML or MDS
This Phase 2 study tests a combination chemotherapy plan (cladribine, low-dose cytarabine, and decitabine) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to shrink the leukemia/MDS and improve outcomes, including for certain people who may not tolerate standard treatment.
Houston, TexasAges 60 years+ - NCT01137643Recruiting
Sharing blood and tissue samples for blood cancer research
This trial collects tissue, blood, and other body fluid samples from people with blood-related cancers. The goal is to help researchers study these diseases by building a source of samples for future testing.
Chapel Hill, North CarolinaAges 18–120 - NCT02074839RecruitingPhase 1
Oral AG-120 for advanced blood cancers with an IDH1 mutation
This Phase 1 study tests an oral medicine called AG-120 in adults with advanced blood cancers that have a specific IDH1 mutation. It also looks at safety and how the treatment works, with frequent blood, urine, and bone marrow samples.
Birmingham, AlabamaAges 18 years+
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myelodysplastic syndromes?
- Yes. Clin2 currently lists 283 recruiting myelodysplastic syndromes studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myelodysplastic syndromes trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myelodysplastic syndromes trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.